15 results on '"Mamdani H"'
Search Results
2. P1.13A.03 MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC
3. MA11.09 Phase II Trial of Atezolizumab Plus Cobimetinib in PD-(L)1 Inhibitor Resistant NSCLC: NCI ETCTN Study 10166
4. EP11.01-10 Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Does Histology Matter?
5. MA06.05 Consolidation Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III NSCLC
6. P76.43 Co-occurring genomic alterations and treatment outcomes in patients with EGFRexon 20 insertion positive NSCLC
7. P1.01-84 Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer
8. P1.01-74 A Retrospective Study Evaluating Clinical Predictors of Duration of Response to Immune Checkpoint Inhibitors in Advanced NSCLC
9. P1.16-27 Risk Factors Associated with a Second Primary Lung Cancer (SPLC) in Patients (Pts) with an Initial Primary Lung Cancer (IPLC)
10. P01.06 CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase
11. MA12.05 Is there a Role for Surgery in Stage I Small Cell Lung Cancer? A National VA Database Analysis
12. P2.01-100 Spectrum of EGFR Exon 20 Insertion Mutations and Co-Occurring Genetic Alterations in Patients with Non-Small-Cell Lung Cancer
13. P2.01-29 The Correlation Between K-Ras Mutant Subsets with TP53 Mutation and PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
14. EP1.01-67 Molecular Profiling of K-Ras and Its Subtypes in NSCLC Patients with Liver Metastasis
15. Phosphazene bases and the anionic oxy-Cope rearrangement
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.